Can using Surgicell (absorbable hemostatic agent) over endometriosis lesions help or harm?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Using Surgicell Over Endometriosis Lesions: Potential Harm vs. Benefit

Using Surgicell (absorbable hemostatic agent) over endometriosis lesions is not recommended as it may potentially harm patients by promoting adhesion formation and interfering with proper visualization and treatment of endometriotic lesions.

Understanding Endometriosis Management

Endometriosis is an inflammatory disease characterized by endometrial-like tissue outside the uterine lining 1. The management of endometriosis requires careful consideration of both medical and surgical approaches:

  • Laparoscopy with histologic confirmation remains the gold standard for diagnosing endometriosis, allowing direct visualization of lesions 2
  • Surgical removal of endometriotic lesions is indicated when medical therapies are ineffective or contraindicated 1
  • Rectosigmoid bowel lesions may require specific surgical approaches including shaving, discoid resection, or segmental resection based on imaging findings 3

Concerns with Using Surgicell on Endometriosis Lesions

Adhesion Formation Risk

  • Absorbable hemostatic agents like Surgicell can potentially promote adhesion formation when placed over endometriotic lesions, which may worsen symptoms and complicate future surgeries 4
  • Endometriosis already has a high recurrence rate (up to 44% within one year after surgery), and additional adhesion formation could exacerbate this issue 4

Interference with Lesion Visualization

  • Proper visualization and classification of endometriotic lesions is crucial for appropriate management 3
  • The World Endometriosis Society recommends that all women undergoing surgery should have complete documentation using the r-ASRM classification, with Enzian classification for deep endometriosis, and EFI for fertility concerns 3
  • Covering lesions with Surgicell may interfere with proper visualization and classification of these lesions 2

Impact on Treatment Efficacy

  • Complete surgical removal of visible lesions is the preferred approach for endometriosis treatment 5
  • Covering lesions with Surgicell instead of properly excising them may lead to incomplete treatment and symptom persistence 5
  • Surgical treatment aims to be therapeutic and effective based on preoperative evaluation, which requires proper visualization and treatment of all lesions 5

Recommended Approaches for Endometriosis Management

Surgical Considerations

  • For deep infiltrating endometriosis, complete excision of lesions is recommended rather than covering them with hemostatic agents 3
  • Surgical planning should be based on proper imaging assessment using transvaginal ultrasound or MRI to determine the extent of disease 3
  • Rectosigmoid endometriotic lesions involving the muscular layer may require discoid or segmental resection, while more superficial lesions can be treated with rectal shaving 3

Post-Surgical Management

  • Combined approach of surgery followed by postoperative medical therapy offers the best long-term outcomes for recurrence of disease and symptoms 5
  • Hormonal medications such as combined oral contraceptives and progestin-only options should be considered after surgery to prevent recurrence 6, 4

Important Considerations and Pitfalls

  • Despite multiple treatment options, there is no medical therapy proven to eradicate endometriosis lesions completely 4
  • The depth of lesions correlates with severity of pain, emphasizing the importance of proper visualization and treatment 4
  • Recurrence rates are high even with optimal treatment, highlighting the importance of not introducing additional factors (like hemostatic agents) that could complicate management 7

In summary, while Surgicell is an effective hemostatic agent in many surgical settings, its use over endometriosis lesions is not recommended due to potential adhesion formation, interference with proper visualization and classification, and possible compromise of treatment efficacy.

References

Research

Endometriosis: A Review.

JAMA, 2025

Guideline

Gold Standard Investigation for Endometriosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pain Management for Endometriosis and Hemorrhagic Cysts

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Surgery for endometriosis: beyond medical therapies.

Fertility and sterility, 2017

Guideline

Endometriosis Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.